Abstract: The morbidity of cholangiocarcinoma has increased in recent years, and the number of Chinese patients with the condition accounts for half of the global number of patients. The treatment for advanced cholangiocarcinoma is no longer limited to palliative surgery; currently, chemotherapy with gemcitabine and cisplatin is used. With the emergence of local therapy (such as hepatic artery perfusions), targeted therapy for specific or multiple mutations, and immunotherapy treatments available after failure of first-line drugs, individualized treatments with relatively mild adverse reactions are now available that provide longer survival time and better quality of life. Here, we summarize the current status of common treatment methods for cholangiocarcinoma and the progress of novel targeted therapies and immunotherapies, with an aim to provide references for clinical practice.